Drugs / CEE321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04612062 | Feb 2020 → May 2021 | atopic eczema | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CEE321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04612062 ↗ |
| Route | Topical | “CEE321 0.2% (3 mg/cm2) topical cream b.i.d.” NCT04612062 ↗ |